2022年5月9日

分享这篇文章提供的新闻分享本文打击士气,加州和南京,中国,5月8日,2022年AskGene从有限的(“AskGene”),临床分期生物制药公司专注于发现和开发的创新生物药物,今天宣布完成首轮融资2000万美元。启明创投融资是由合作伙伴和TF资本。所得资金将用于推进AskGene临床发展的强有力的研发创新治疗候选人和发展SmartKine®细胞因子前体药物平台。细胞因子在免疫治疗验证co-stimulators和蕴含着巨大的希望,然而,他们有短的半衰期,严重的系统性毒性和狭窄的治疗窗。SmartKine®是一个转换细胞因子AskGene开发的技术平台与全球知识产权。技术克服了当前细胞因子疗法的局限性,给患者带来下一代细胞因子治疗未满足的医疗需求。SmartKine®分子设计选择性地激活免疫细胞的一个子集优先在疾病位点选择性提高功能,可展性和细胞因子治疗指数。“我们很高兴支持一流的投资者分享我们的愿景与精密调节免疫系统疾病地点,”杰夫说,首席执行官AskGene有限。“这是我们公司的一个令人激动的时刻。我们正在几个潜在first-in-class或最佳分子从我们SmartKine®平台,今年晚些时候临床前开发和临床开发。 In addition, our clinical programs ASKB589 and ASKG712 are progressing smoothly. We look forward to promising results from multiple clinical programs later this year and next year." "Cancer is still one of the major disease burdens for patients and IO has demonstrated its effectiveness", stated William Hu, Managing Partner of Qiming Venture Partners, "AskGene's team shows deep understanding in IO and protein engineering. We believe their proprietary platform continues to generate more pipelines to clinic and market." Allan Liu, Director at TF Capital commented: "Application of immunostimulatory cytokines has become a promising approach in cancer immunotherapy, however unfavorable PK and safety profile limit their further clinical development and application. AskGene's proprietary SmartKine® platform can overcome limitations of first-generation recombinant cytokines by achieving conditional activation of cytokines in the tumor microenvironment to unleash the full therapeutic potential. We are thrilled to partner with AskGene's exceptional leadership team as they advance SmartKine® molecules into the clinic with the ultimate goal of providing better outcomes to cancer patients." About Qiming Venture Partners Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently Qiming Venture Partners manages ten US Dollar funds and six RMB funds with over $6.2 billion in AUM capital raised. Since its establishment, Qiming Venture Partners has invested in outstanding companies in the TMT and healthcare industries at the early and growth stages. Since its debut, Qiming Venture Partners has backed over 430 fast-growing and innovative companies. Over 170 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 40 portfolio companies that have achieved unicorn status. About TF Capital TF Capital focuses on investment in the life sciences industry, primarily investing in early-stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies. About AskGene AskGene is an innovative company advancing immunotherapies for cancers and autoimmune diseases. The vision of the company is to apply next-generation platform technology to unlock the full therapeutic potential of cytokines with better safety profiles. Through its SmartKine® platform technology and pipeline programs, AskGene aspires to achieve its overarching objective of modulating immune system at a disease site with selectivity and precision. Additional clinical stage programs include ASKB589 (an anti-CLDN 18.2 antibody in phase I/II) and ASKG712 (an anti-VEGF antibody-ANG2 antagonist peptide fusion molecule in phase I). SOURCE AskGene Limited